Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Genus Capital Management Inc.

Genus Capital Management Inc. cut its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 8.6% during the second quarter, HoldingsChannel.com reports. The fund owned 4,370 shares of the pharmaceutical company’s stock after selling 410 shares during the period. Genus Capital Management Inc.’s holdings in Vertex Pharmaceuticals were worth $1,946,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of VRTX. Activest Wealth Management acquired a new position in Vertex Pharmaceuticals during the first quarter worth $25,000. Clal Insurance Enterprises Holdings Ltd increased its stake in Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 45 shares during the period. Access Investment Management LLC purchased a new stake in shares of Vertex Pharmaceuticals in the 2nd quarter valued at approximately $27,000. Flaharty Asset Management LLC purchased a new stake in shares of Vertex Pharmaceuticals in the 1st quarter valued at approximately $32,000. Finally, American National Bank & Trust grew its position in shares of Vertex Pharmaceuticals by 515.4% in the 2nd quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock valued at $36,000 after buying an additional 67 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on VRTX shares. Evercore ISI dropped their target price on shares of Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating on the stock in a research report on Thursday, September 11th. Stifel Nicolaus dropped their target price on shares of Vertex Pharmaceuticals from $455.00 to $445.00 and set a “hold” rating on the stock in a research report on Tuesday. Raymond James Financial started coverage on shares of Vertex Pharmaceuticals in a research report on Tuesday, September 2nd. They issued a “market perform” rating on the stock. Morgan Stanley dropped their target price on shares of Vertex Pharmaceuticals from $439.00 to $438.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Finally, Truist Financial set a $490.00 price objective on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $489.45.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $421.67 on Wednesday. The stock has a fifty day moving average price of $403.14 and a 200 day moving average price of $430.65. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.88. The company has a market cap of $108.11 billion, a PE ratio of 30.14 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share for the quarter, topping the consensus estimate of $4.58 by $0.22. The firm had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The company’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same period last year, the company earned $4.38 earnings per share. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.